ACTRN12623001071617
Not yet recruiting
Phase 1
Investigating Safety and Preliminary Efficacy of TargEting LysyL oxIdase tO ameliorate scarring in burn Trauma
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- burn injury
- Sponsor
- university of western australia
- Enrollment
- 60
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Aged between 21 and 60 years (inclusive).
- •2\.Acute burn injury of \>\=5% and \<\=15% total body surface area (TBSA) requiring treatment with a split\-thickness skin graft
- •3\.Agree to use of adequate contraception if participant/partner of childbearing age.
- •4\.Have given written informed consent to participate in this study in accordance with local regulations.
- •5\. Able to understand, give consent, and comply with all scheduled study visits, procedures and restrictions.
Exclusion Criteria
- •1\.Clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, skin, or cardiovascular disease or any other condition, that, in the opinion of the Principal Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
- •2\.History of immediate hypersensitivity to any medication or currently suffers from clinically significant systemic allergic disease.
- •3\.Alanine aminotransferase (ALT) and/or), aspartate aminotransferase (AST) \>3\.0 x), or bilirubin\>2\.5 × upper limit of normal (ULN) or direct bilirubin \>1\.5 ULN.).
- •4\.Evidence of significant renal insufficiency, as indicated by an estimated creatinine clearance using the Cockcroft\-Gault formula of less than 50 mL/min at Screening.
- •5\.Have participated in a clinical trial or have received an experimental therapy within 30 days or 5 half\-lives of the drug, whichever is longer, prior to dosing.
- •6\.Active systemic infection
- •7\.History of aneurysm
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Phase I study for the efficacy and the safety of the perioperative urinastatin therapy in chest surgical patients with interstitial pneumonia.interstitial pneumonia, lung cancer, metastatic lung tumor, pneumothoraxJPRN-UMIN000003295Tokyo Women's Medical University of Medicine, Department of Surgery I30
Recruiting
Phase 1
Investigation of fractional CO2 laser and adipose tissue exosome in the treatment of acne scars and skin rejuvenatioCondition 1: Skin aging. Condition 2: Atrophic scar.Atrophic disorder of skinScar conditions and fibrosis of skinL90.9L90.5IRCT20200127046282N52Tehran University of Medical Sciences16
Completed
Not Applicable
The evaluation of the efficacy and the safety of TSUMURA Tokishakuyakusan Extract Granules for Ethical Use on endometriosis patients with dysmenorrheaEndometriosisJPRN-UMIN000017908Tottori University Faculty of Medicine15
Completed
Not Applicable
Safety and Efficacy of the Adapt Pericardial Patch in the repair of defects associated with congenital heart disease in participants aged between 1 and 12 years of ageCongenital Heart Disease including ventricular septal defect repair, atrial ventricular septal defect, atrio ventricular septal defects as determined by clinical assessment including MRI and echo cardiographyCardiovascular - Other cardiovascular diseasesACTRN12613000308796A/Professor Christian Brizard40
Recruiting
Phase 3
Study of Out of Specification for TisagenlecleucelPediatric/young adult patients with r/r pALL and adult patients with r/r LBCL (including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma) for Part 1, and r/r ALL and r/r NHL for Part 2.JPRN-jRCT1080224903ovartis Pharma. K.K.200